The Mesoblast Ltd (ASX: MSB) share price is in focus after the company reported Ryoncil® net sales of US$30.3 million for the March 2026 quarter, bringing total net revenue since launch to nearly US$100 million.
Image source: Getty Images
What did Mesoblast report?
- Net sales for Ryoncil® reached US$30.3 million in the third quarter to March 2026
- Revenue since Ryoncil® launch now approaches US$100 million
- Strong sales growth in February and March offset a seasonal dip in January
- Ryoncil® is the only FDA-approved cell therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD)
What else do investors need to know?
Mesoblast's first year of Ryoncil® sales has boosted its balance sheet and is helping to fund label extensions and late-stage clinical programs. The company reiterated its leadership role by being first to market with an FDA-approved mesenchymal stromal cell therapy.
Mesoblast will host its first R&D Day in New York on 8 April 2026, where it will outline growth strategies for Ryoncil® and provide updates on its late-stage product pipeline. Investors can join the live webcast or access a replay on the company's website.
What's next for Mesoblast?
The company is focusing on expanding Ryoncil®'s approved uses, including studies in adults with SR-aGvHD and in biologic-resistant inflammatory bowel disease. Mesoblast is also progressing clinical development of rexlemestrocel-L for heart failure and chronic low back pain.
Ongoing investment in its product pipeline and global partnerships should ensure Mesoblast stays at the cutting edge of cell therapy for major inflammatory diseases.
Mesoblast share price snapshot
Over the past 12 months, Mesoblast shares have risen 29%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 20% over the same period.
